Osteoarthritis - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Osteoarthritis - Pipeline Review, H2 2018’, provides an overview of the Osteoarthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteoarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Osteoarthritis

- The report reviews pipeline therapeutics for Osteoarthritis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Osteoarthritis therapeutics and enlists all their major and minor projects

- The report assesses Osteoarthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Osteoarthritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Osteoarthritis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Osteoarthritis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4P-Pharma SAS

AbbVie Inc

Abiogen Pharma SpA

Ablynx NV

Amgen Inc

Arthrogen BV

AVM Biotechnology LLC

Axsome Therapeutics Inc

Biopharm GmbH

Bone Therapeutics SA

Cardax ...

4P-Pharma SAS

AbbVie Inc

Abiogen Pharma SpA

Ablynx NV

Amgen Inc

Arthrogen BV

AVM Biotechnology LLC

Axsome Therapeutics Inc

Biopharm GmbH

Bone Therapeutics SA

Cardax Inc

Cells for Cells SA

Cellular Biomedicine Group Inc

Chugai Pharmaceutical Co Ltd

Corestem Inc

Daewoong Co Ltd

Daewoong Pharmaceutical Co Ltd

Eli Lilly and Co

Ensol Biosciences Inc

Evgen Pharma Plc

EyePoint Pharmaceuticals Inc

Flexion Therapeutics Inc

Galapagos NV

Gemphire Therapeutics Inc

Genequine Biotherapeutics GmbH

GlaxoSmithKline Plc

InKemia IUCT Group SA

International Stem Cell Corp

Jeil Pharmaceutical Co Ltd

K-Stemcell Co Ltd

Kang Stem Biotech Co Ltd

Kolon TissueGene Inc

Lateral Pharma Pty Ltd

Levolta Pharmaceuticals Inc

LG Chem Ltd

Marina Biotech Inc

Medivir AB

Medy-Tox Inc

Merck KGaA

Mesoblast Ltd

Mor Research Application Ltd

Nordic Bioscience AS

Novartis AG

NovelMed Therapeutics Inc

Paradigm Biopharmaceuticals Ltd

Pfizer Inc

Philogen SpA

PhytoHealth Corp

PLx Pharma Inc

Progenitor Therapeutics Ltd

ProteoThera Inc

Regeneus Ltd

Regulaxis SAS

Rottapharm Biotech Srl

Samumed LLC

Seikagaku Corp

Stempeutics Research Pvt Ltd

Takeda Pharmaceutical Co Ltd

Traverse Biosciences Inc

Unity Biotechnology Inc

WEX Pharmaceuticals Inc

Xintela AB

Yooyoung Pharm Co Ltd

Zimmer Biomet Holdings Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Osteoarthritis – Overview 7

Osteoarthritis – Therapeutics Development 8

Osteoarthritis – Therapeutics Assessment 21

Osteoarthritis – Companies Involved in Therapeutics ...

Table of Contents

Table of Contents 2

Introduction 6

Osteoarthritis – Overview 7

Osteoarthritis – Therapeutics Development 8

Osteoarthritis – Therapeutics Assessment 21

Osteoarthritis – Companies Involved in Therapeutics Development 31

Osteoarthritis – Drug Profiles 60

Osteoarthritis – Dormant Projects 240

Osteoarthritis – Discontinued Products 248

Osteoarthritis – Product Development Milestones 250

Appendix 262

List of Tables

List of Tables

Number of Products under Development for Osteoarthritis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Osteoarthritis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Osteoarthritis – Pipeline by 4P-Pharma SAS, H2 2018

Osteoarthritis – Pipeline by AbbVie Inc, H2 2018

Osteoarthritis – Pipeline by Abiogen Pharma SpA, H2 2018

Osteoarthritis – Pipeline by Ablynx NV, H2 2018

Osteoarthritis – Pipeline by Amgen Inc, H2 2018

Osteoarthritis – Pipeline by Arthrogen BV, H2 2018

Osteoarthritis – Pipeline by AVM Biotechnology LLC, H2 2018

Osteoarthritis – Pipeline by Axsome Therapeutics Inc, H2 2018

Osteoarthritis – Pipeline by Biopharm GmbH, H2 2018

Osteoarthritis – Pipeline by Bone Therapeutics SA, H2 2018

Osteoarthritis – Pipeline by Cardax Inc, H2 2018

Osteoarthritis – Pipeline by Cells for Cells SA, H2 2018

Osteoarthritis – Pipeline by Cellular Biomedicine Group Inc, H2 2018

Osteoarthritis – Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018

Osteoarthritis – Pipeline by Corestem Inc, H2 2018

Osteoarthritis – Pipeline by Daewoong Co Ltd, H2 2018

Osteoarthritis – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018

Osteoarthritis – Pipeline by Eli Lilly and Co, H2 2018

Osteoarthritis – Pipeline by Ensol Biosciences Inc, H2 2018

Osteoarthritis – Pipeline by Evgen Pharma Plc, H2 2018

Osteoarthritis – Pipeline by EyePoint Pharmaceuticals Inc, H2 2018

Osteoarthritis – Pipeline by Flexion Therapeutics Inc, H2 2018

Osteoarthritis – Pipeline by Galapagos NV, H2 2018

Osteoarthritis – Pipeline by Gemphire Therapeutics Inc, H2 2018

Osteoarthritis – Pipeline by Genequine Biotherapeutics GmbH, H2 2018

Osteoarthritis – Pipeline by GlaxoSmithKline Plc, H2 2018

Osteoarthritis – Pipeline by InKemia IUCT Group SA, H2 2018

Osteoarthritis – Pipeline by International Stem Cell Corp, H2 2018

Osteoarthritis – Pipeline by Jeil Pharmaceutical Co Ltd, H2 2018

Osteoarthritis – Pipeline by K-Stemcell Co Ltd, H2 2018

Osteoarthritis – Pipeline by Kang Stem Biotech Co Ltd, H2 2018

Osteoarthritis – Pipeline by Kolon TissueGene Inc, H2 2018

Osteoarthritis – Pipeline by Lateral Pharma Pty Ltd, H2 2018

Osteoarthritis – Pipeline by Levolta Pharmaceuticals Inc, H2 2018

Osteoarthritis – Pipeline by LG Chem Ltd, H2 2018

Osteoarthritis – Pipeline by Marina Biotech Inc, H2 2018

Osteoarthritis – Pipeline by Medivir AB, H2 2018

Osteoarthritis – Pipeline by Medy-Tox Inc, H2 2018

Osteoarthritis – Pipeline by Merck KGaA, H2 2018

Osteoarthritis – Pipeline by Mesoblast Ltd, H2 2018

Osteoarthritis – Pipeline by Mor Research Application Ltd, H2 2018

Osteoarthritis – Pipeline by Nordic Bioscience AS, H2 2018

Osteoarthritis – Pipeline by Novartis AG, H2 2018

Osteoarthritis – Pipeline by NovelMed Therapeutics Inc, H2 2018

Osteoarthritis – Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2018

Osteoarthritis – Pipeline by Pfizer Inc, H2 2018

Osteoarthritis – Pipeline by Philogen SpA, H2 2018

Osteoarthritis – Pipeline by PhytoHealth Corp, H2 2018

Osteoarthritis – Pipeline by PLx Pharma Inc, H2 2018

Osteoarthritis – Pipeline by Progenitor Therapeutics Ltd, H2 2018

Osteoarthritis – Pipeline by ProteoThera Inc, H2 2018

Osteoarthritis – Pipeline by Regeneus Ltd, H2 2018

Osteoarthritis – Pipeline by Regulaxis SAS, H2 2018

Osteoarthritis – Pipeline by Rottapharm Biotech Srl, H2 2018

Osteoarthritis – Pipeline by Samumed LLC, H2 2018

Osteoarthritis – Pipeline by Seikagaku Corp, H2 2018

Osteoarthritis – Pipeline by Stempeutics Research Pvt Ltd, H2 2018

Osteoarthritis – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Osteoarthritis – Pipeline by Traverse Biosciences Inc, H2 2018

Osteoarthritis – Pipeline by Unity Biotechnology Inc, H2 2018

Osteoarthritis – Pipeline by WEX Pharmaceuticals Inc, H2 2018

Osteoarthritis – Pipeline by Xintela AB, H2 2018

Osteoarthritis – Pipeline by Yooyoung Pharm Co Ltd, H2 2018

Osteoarthritis – Pipeline by Zimmer Biomet Holdings Inc, H2 2018

Osteoarthritis – Dormant Projects, H2 2018

Osteoarthritis – Dormant Projects, H2 2018 (Contd..1), H2 2018

Osteoarthritis – Dormant Projects, H2 2018 (Contd..2), H2 2018

Osteoarthritis – Dormant Projects, H2 2018 (Contd..3), H2 2018

Osteoarthritis – Dormant Projects, H2 2018 (Contd..4), H2 2018

Osteoarthritis – Dormant Projects, H2 2018 (Contd..5), H2 2018

Osteoarthritis – Dormant Projects, H2 2018 (Contd..6), H2 2018

Osteoarthritis – Discontinued Products, H2 2018

Osteoarthritis – Discontinued Products, H2 2018 (Contd..1), H2 2018

List of Figures

List of Figures

Number of Products under Development for Osteoarthritis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Figures

Number of Products under Development for Osteoarthritis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports